Send to:

Choose Destination
See comment in PubMed Commons below
Gastroenterology. 1993 Feb;104(2):519-26.

Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial.

Author information

  • 1Institute of Liver Studies, King's College Hospital, London, England.



Effective treatment for primary biliary cirrhosis (PBC) resulting in slower progression and improved survival remains elusive. Cyclosporin A (CyA), which has been so effective in preventing human allograft rejection, has shown promise in small numbers of patients in early studies.


Three hundred forty-nine patients with PBC were randomized to receive CyA, 3, or placebo in a multicenter study with follow-up for 6 years. The end point was death or liver transplantation.


Cox multivariate analysis showed time from entry to death or transplantation was significantly prolonged (by up to 50%) in the CyA-treated group. Liver-related mortality was also significantly lower. However, a univariate analysis of survival showed no statistical differences between the two groups. Biochemical liver indices deteriorated more slowly in the CyA-treated group, but serum creatinine concentration was elevated > 150 mumol/L in 9%, necessitating permanent discontinuation in half of these. A reduction in the dose of CyA was required in 11% because of hypertension.


CyA has some therapeutic potential in primary biliary cirrhosis, providing blood pressure and renal function are closely monitored.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk